Cellebrite: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 12, 2026, Cellebrite (NASDAQ:CLBT) reported annual recurring revenue, the annualized value of active subscription contracts, grew 20% year over year to $528.5 million. The digital forensics provider is shifting from single-device data extraction tools into an artificial intelligence investigative software platform. Three things management said stand out.

1. Artificial Intelligence Platform Genesis Delivers Immediate Revenue Growth

Management launched Genesis, an artificial intelligence tool that searches evidence like video and audio calls to surface investigative leads in minutes. Customers reprioritized spending to buy it during the quarter, generating $2 million in annual recurring revenue in its first full quarter.

Genesis finished Q3 with $2 million in ARR as we continued to see strong adoption by customers. Perhaps most telling, Genesis was not in our customers’ annual budgets this year.
— Shiven Ramji, Chief Executive Officer

2. Redomiciling to the United States Removes Procurement Friction

Foreign entity status created sales delays in the U.S. and Europe. Management plans to complete a redomiciliation to the United States in the first half of 2027 to eliminate hurdles to purchasing and gain eligibility for major U.S. stock indices.

Redomiciling is a strategic evolution that we believe better positions us to drive growth in our largest market and beyond.
— Shiven Ramji, Chief Executive Officer

3. Conversion Uplift From Core Forensic Software Is Tapering Off

Upgrades to Inseyets, the company’s flagship mobile device forensic extraction software, reached 75% of the customer base at the end of the quarter. Management expects the remaining quarter of customer upgrades to yield smaller price increases and fewer expansion sales than prior tranches.

It is clear, however, that the final tranche of conversions will produce a lighter uplift and fewer expansions than we experienced in the prior two years. This trend remains embedded in our outlook.
— David Barter, Chief Financial Officer

Looking Ahead

Free cash flow margin is tracking toward 30% for the full year as subscription revenue hits 91% of sales. The business relies on high switching costs from deep workflow integration and proprietary decryption tools, while leadership tracks ratable revenue execution across multiyear renewals.

Overall, we are well-positioned from a free cash flow perspective and expect to produce a full-year FCF margin of approximately 30%.
— David Barter, Chief Financial Officer

Expanding the artificial intelligence platform positions the business to consolidate fragmented law enforcement contracts into single subscription agreements.

We are increasingly confident that the Genesis platform strengthens the foundation upon which we will drive durable ARR growth, a more predictable revenue profile, and over time, higher levels of profitability and free cash flow.
— Shiven Ramji, Chief Executive Officer

Should you buy stock in Cellebrite right now?

Before you buy stock in Cellebrite, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cellebrite wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 14, 2026.

The Motley Fool has positions in and recommends Cellebrite. The Motley Fool has a disclosure policy.

Cellebrite: 3 Key Takeaways for Long-Term Investors was originally published by The Motley Fool